Phase II study of low-dose peginterferon alfa-2b antiangiogenic therapy in patients with metastatic melanoma overexpressing basic fibroblast growth factor: An Eastern Cooperative Oncology Group study (E2602).
Ronald S. Go
No relevant relationships to disclose
Sandra J. Lee
No relevant relationships to disclose
Donghoon Shin
No relevant relationships to disclose
Steven M Callister
No relevant relationships to disclose
Dean A Jobe
No relevant relationships to disclose
Robert Martin Conry
No relevant relationships to disclose
Ahmad A. Tarhini
No relevant relationships to disclose
John M. Kirkwood
No relevant relationships to disclose